
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
The American Journal of Managed Care
almost 26 years ago
Disease Management for Diabetes Mellitus: Impact on Hemoglobin A1Calmost 26 years ago
Is the Gatekeeper Just Another Buggy Whip?almost 26 years ago
Show Me the Money: Medical Directors' Responses to a Mail Survey




